Hematology Biobank : Invitro Study of Blood Disorders

Overview

This is a bio repository of blood specimens from subjects with different Hematological disorders.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2025

Detailed Description

There has been a marked increase in our knowledge of Blood Disorders in the last decade. Much of this knowledge comes from examining blood specimens from patients and subjecting these samples to red cell, plasma, serum or DNA analyses. We propose to set up a Hematology biobank, which will include patient histories, their medical progress and a linked but de-identified bank of blood samples. This will enable us to have a large database, which can be used to learn more about these diseases. The Hematology biobank will use whole blood, red blood cells, plasma, serum and/or DNA.

Clinical Trial Outcome Measures

Primary Measures

  • Biobank
    • Time Frame: 5 years
    • To have specimens available for IRB approved studies

Participating in This Clinical Trial

Inclusion Criteria

Above 18 years of age and able to consent Exclusion Criteria:

None

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Albert Einstein College of Medicine
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Henny Billett, Principal Investigator, Albert Einstein College of Medicine
  • Overall Contact(s)
    • Swati Goel, 7189204137, swgoel@montefiore.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.